Chimera Research Group

previous arrow
next arrow

April 30th Biotech Update

The sector could be doing worse but even with bad economic numbers and the market down a little, the sector is not only holding up well it is actually green (marginally so but still green when the market is red).  This lends credence to my belief that we may have put in a long term […]

April 29th Biotech Update

I see a lot more green on my screen than the XBI seems to indicate but I see this as generally a productive day for the sector.  There is a lot of news to digest that just came out today and so some I may leave until tomorrow.  Overall, I still think we have likely […]

April 28th Biotech Update

Is the sector finally setup to succeed? We have had a sharp rally off of that dip into the mid-$60 and that was also a real peak in negativity.  Anyone who had any inclination or desire to see has likely sold in that dip.  If that did not shake out weak or even stronger hands […]

April 14th Biotech Update

Volatility is the name of the game.  Uncertainty breeds caution and is not a good setup for investments. You are not going to build out capacity if you do not know future costs or demand.  This is why everyone is fearing a recession and the move into a bear market.  Bear markets are quite dangerous […]

Mailing List

Introduction

Play
Current Time 0:00
/
Duration Time 0:00
Remaining Time -0:00
Loaded: 0%
Progress: 0%
0:00
Fullscreen
00:00
Mute

Overview

Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.

Subscribe to Chimera Research Group and proceed with confidence.

Get Started

Recent Press

Log In

JoinLost Password?